TABLE 3.

Comparison of in vitro susceptibilities of BSI isolates of Candida collected before (2004 to 2005) and after (2008 to 2009) the clinical introduction of micafungin in North Americaa

SpeciesYrNo. of isolates testedNo. of isolates by MIC (μg/ml)
0.0070.0150.030.060.120.250.51248
C. albicans2004-2005b358362327713
2008-2009406811121176
C. glabrata2004-2005b1957167125121
2008-20092202261107241221
C. parapsilosis2004-2005b1015144438
2008-20091601111129747
C. tropicalis2004-2005b502131417211
2008-20099863745721
C. krusei2004-2005b1411021
2008-20091596
  • a All isolates tested using CLSI broth microdilution methods.

  • b Data compiled from the work of Pfaller et al. (13).